Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of “Buy” from Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been given an average rating of “Buy” by the eight brokerages that are covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $6.63.

Several research analysts have recently issued reports on TSHA shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Canaccord Genuity Group increased their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Chardan Capital reiterated a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. JMP Securities reissued a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, Needham & Company LLC reissued a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a report on Monday, January 6th.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in shares of Taysha Gene Therapies by 23.7% during the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock valued at $7,163,000 after purchasing an additional 682,273 shares in the last quarter. Wellington Management Group LLP purchased a new position in Taysha Gene Therapies in the third quarter worth about $931,000. Charles Schwab Investment Management Inc. grew its position in Taysha Gene Therapies by 7.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock worth $930,000 after acquiring an additional 33,123 shares in the last quarter. Barclays PLC boosted its position in shares of Taysha Gene Therapies by 356.0% during the third quarter. Barclays PLC now owns 247,280 shares of the company’s stock valued at $513,000 after buying an additional 193,046 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in shares of Taysha Gene Therapies during the second quarter valued at approximately $1,018,000. 77.70% of the stock is owned by institutional investors.

Taysha Gene Therapies Trading Down 3.2 %

TSHA opened at $1.53 on Monday. The business has a 50 day simple moving average of $2.14 and a two-hundred day simple moving average of $2.11. The firm has a market capitalization of $313.56 million, a price-to-earnings ratio of 2.43 and a beta of 0.95. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. Taysha Gene Therapies has a one year low of $1.19 and a one year high of $4.32.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.